You are viewing a free limited preview of Par Pharmaceutical Companies, Inc.
Get Full Access To This Report 
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
Par Pharmaceutical Companies, Inc. is a privately-held company that engages in developing and distributing generic and branded pharmaceutical products primarily in the United States. The company offers prescription drugs in the solid oral dosage forms, such as tablets, caplets, and two-piece hard-shell capsules; oral suspension products; nasal spray products; and products delivered by injection. The company markets its products primarily to wholesalers, drug store chains, supermarket chains, mass merchandisers, distributors, mail order accounts, clinics, governmental agencies, and other managed health care organizations. Par Pharmaceutical Companies, Inc. was founded in 1978 and is headquartered in Woodcliff Lake, New Jersey.
| Fiscal Year End: | 12/31 |
| City: | Woodcliff Lake |
| State/Province: | New Jersey |
| Country: | United States |
| Phone: | View |
| Website: | www.parpharm.com |
| Subsidiaries: | Par Pharmaceutical, Inc. Strativa Pharmaceuticals |
| Brands: | Nascobal Nasal Spray Prozac Klonopin Zantac |
| Healthcare > Pharmaceuticals |
| Manufacturing & Industrial > Chemical Manufacturing > Biochemicals |
The PrivCo Industry Classification System™ (PICS) is our proprietary, modernized industry classification system, geared especially toward privately-held companies and including newer emerging sub-industries that are not reflected in other outdated industry classification systems, such as SIC and NAICS.
Export All Par Pharmaceutical Companies, Inc. Financials To Excel
$99 Single Company AccessInstant Full Site-Wide Access| Income Statement | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
| Sales Revenue, Net - Goods | View | View | $641,000 | $861,000 | $1,257,000 | $1,285,000 | $1,221,000 | $1,701,000 | $1,335,000 | $1,732,000 |
| Sales Revenue, Net - Services | View | View | $304,466,000 | $280,709,000 | $263,297,000 | $250,543,000 | $248,074,000 | $240,733,000 | $213,384,000 | $169,527,000 |
| Revenues | View | View | $305,107,000 | $281,570,000 | $264,554,000 | $251,828,000 | $249,295,000 | $242,434,000 | $214,719,000 | $171,259,000 |
| Cost of Goods Sold | View | View | $384,000 | $470,000 | $780,000 | $891,000 | $580,000 | $830,000 | $821,000 | $1,268,000 |
| Selling, General and Administrative Expenses | View | View | $42,208,000 | $39,167,000 | $37,655,000 | $33,832,000 | $37,123,000 | $38,576,000 | $31,196,000 | $26,386,000 |
| Write Off Asset | $1,707,000 | |||||||||
| Nonrecurring Gain | $3,482,000 | $720,000 | ($121,000) | ($359,000) | ($1,049,000) | $0 | $0 | |||
| Depreciation and Amortization | View | View | $29,908,000 | $28,442,000 | $30,367,000 | $27,697,000 | $28,858,000 | $26,402,000 | $22,298,000 | $16,981,000 |
| Restructuring Charges | $567,000 | $432,000 | ||||||||
| Merger and Acquisitions Costs | $926,000 | |||||||||
| Asset Impairment Charges | View | View | $143,000 | $517,000 | $316,000 | $0 | $0 | |||
| Expense | View | View | $204,990,000 | $189,204,000 | $171,062,000 | $161,165,000 | $157,980,000 | $149,267,000 | $133,923,000 | $105,633,000 |
| Cost and Operating Expenses | View | View | $276,259,000 | $254,234,000 | $240,011,000 | $223,973,000 | $224,900,000 | $216,691,000 | $188,670,000 | $151,194,000 |
| Operating Income/(Loss) | View | View | $28,848,000 | $27,336,000 | $24,543,000 | $27,855,000 | $24,395,000 | $25,743,000 | $26,049,000 | $20,065,000 |
| Interest Expense | View | View | $9,833,000 | $9,931,000 | $9,891,000 | $11,377,000 | $14,259,000 | $14,637,000 | $8,653,000 | $4,812,000 |
| Interest Income | View | View | $96,000 | $128,000 | $141,000 | $213,000 | $1,276,000 | $1,634,000 | $1,287,000 | $93,000 |
| Gain/(Loss) on Disposition of Property | View | View | $1,374,000 | $1,274,000 | ($350,000) | $49,000 | ||||
| Non-operating Income - Other | View | View | $231,000 | $304,000 | $96,000 | $588,000 | $214,000 | $32,000 | $441,000 | $538,000 |
| Non-operating Income/(Expense) | View | View | ($9,506,000) | ($9,499,000) | ($9,654,000) | ($10,576,000) | ($12,769,000) | ($12,971,000) | ($6,925,000) | ($4,181,000) |
| Income/(Loss) from Continuing Operations Before Income Taxes | View | View | $19,342,000 | $17,837,000 | $12,772,000 | $19,124,000 | $15,884,000 | |||
| Income Loss Continuing Operations Before Income Taxes Minority Interest Effect Change Accounting Principle | $14,889,000 | |||||||||
| Income Loss Continuing Operations Before Income Taxes Effect Accounting Change | $17,279,000 | $11,626,000 | ||||||||
| Provision for Income Taxes | View | View | $7,792,000 | $6,588,000 | $6,108,000 | $6,317,000 | $4,244,000 | $5,113,000 | $7,100,000 | $5,606,000 |
| Income/(Loss) Before Cumulative Effect of Change in Accounting Principle | $8,781,000 | $10,962,000 | $7,382,000 | |||||||
| Cumulative Effect of a Change in Accounting Principle, Net of Tax Effect | ($1,067,000) | $0 | $0 | |||||||
| Income/(Loss) from Continuing Operations | View | View | $11,550,000 | $11,249,000 | ||||||
| Income/(Loss) from Discontinued Operations | View | View | $454,000 | $548,000 | $109,000 | |||||
| Income/(Loss) from Discontinued Operations, Net of Tax Effect | View | View | $639,000 | $548,000 | $109,000 | |||||
| Income/(Loss) from Disposition of Discontinued Operations | View | View | $185,000 | $0 | $0 | |||||
| Net Income (Loss) | View | View | $12,189,000 | $11,797,000 | $7,823,000 | $10,962,000 | $7,382,000 | $7,659,000 | $12,024,000 | $10,278,000 |
| Preferred Stock Dividends | ($1,077,000) | $0 | ||||||||
| Net Income Pro Forma Before Adjustment | $15,884,000 | |||||||||
| Pro-Forma Adjustment | ($5,803,000) | |||||||||
| Total Net Income Pro Forma | $10,081,000 |
| Balance Sheet | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
| Cash and Cash Equivalents | View | View | $1,575,000 | $2,445,000 | $4,127,000 | $1,734,000 | $1,887,000 | $7,401,000 | $3,176,000 |
| Net Accounts Receivable Trade | View | View | $34,541,000 | $30,134,000 | $31,235,000 | $28,200,000 | $26,307,000 | $27,983,000 | $26,756,000 |
| Other Accounts and Notes Receivable | View | View | $1,376,000 | $1,468,000 | $1,182,000 | $1,351,000 | $663,000 | $0 | |
| Net Income Taxes Receivable | $919,000 | $0 | $857,000 | $0 | |||||
| Net Other Receivables | $1,395,000 | ||||||||
| Current Amounts Due From Employee | $276,000 | $0 | |||||||
| Inventories - Supplies | $1,547,000 | ||||||||
| Net Inventories | View | View | $1,526,000 | $1,427,000 | $1,552,000 | $1,541,000 | $1,778,000 | $1,617,000 | |
| Current Deferred Income Taxes | View | View | $1,524,000 | $2,740,000 | $1,350,000 | $759,000 | $2,337,000 | $1,183,000 | $910,000 |
| Prepaid Insurance | View | View | $180,000 | $494,000 | $473,000 | $626,000 | |||
| Other Prepaid Expenses | $2,257,000 | $2,981,000 | $3,620,000 | ||||||
| Prepaid Expenses | $2,762,000 | $2,438,000 | $3,017,000 | ||||||
| Current Other Assets | View | View | $869,000 | ||||||
| Current Assets | View | View | $41,888,000 | $41,075,000 | $41,759,000 | $37,310,000 | $36,877,000 | $44,111,000 | $35,476,000 |
| Net Property, Plant and Equipment | View | View | $216,390,000 | $198,551,000 | $191,309,000 | $189,954,000 | $197,274,000 | $193,295,000 | $138,530,000 |
| Noncurrent Amounts Due From Employee | $232,000 | ||||||||
| Noncurrent Derivative Assets | $0 | ||||||||
| Goodwill | View | View | $97,115,000 | $87,902,000 | $85,957,000 | ||||
| Intangible Assets - Other | View | View | $8,810,000 | $4,800,000 | $4,165,000 | ||||
| Net Intangible Assets | $67,791,000 | $66,519,000 | $67,918,000 | $71,458,000 | |||||
| Deferred Financing Costs | $1,662,000 | ||||||||
| Restricted Cash | View | View | $552,000 | $0 | $822,000 | $0 | |||
| Noncurrent Other Assets | View | View | $3,400,000 | $4,488,000 | $6,516,000 | $1,856,000 | $2,135,000 | $2,424,000 | $3,740,000 |
| Assets | View | View | $368,155,000 | $337,048,000 | $330,528,000 | $298,573,000 | $302,805,000 | $307,748,000 | $249,204,000 |
| Accounts Payable - Trade | View | View | $16,579,000 | $14,627,000 | $13,299,000 | $10,501,000 | $10,512,000 | $12,178,000 | $12,109,000 |
| Interest Payable | $1,321,000 | $1,457,000 | $2,462,000 | $777,000 | |||||
| Accrued Salaries | $3,860,000 | $3,647,000 | $2,003,000 | $1,619,000 | |||||
| Self Insurance | View | View | $4,661,000 | $3,406,000 | |||||
| Other Employee Related Liabilities | View | View | $4,258,000 | $3,717,000 | |||||
| Employee Related Liabilities | $6,052,000 | ||||||||
| Other Accrued Expenses | View | View | $6,065,000 | $4,488,000 | $8,753,000 | $5,253,000 | $3,568,000 | $1,745,000 | $1,687,000 |
| Current Deferred/(Unearned) Revenue | View | View | $6,707,000 | $5,949,000 | $2,421,000 | $1,997,000 | $1,800,000 | $1,884,000 | $1,875,000 |
| Income Taxes Payable | View | View | $3,844,000 | $410,000 | $0 | $84,000 | $0 | $1,487,000 | |
| Current Portion of Long-Term Debt | View | View | $10,733,000 | $10,733,000 | $10,723,000 | $11,710,000 | $7,498,000 | $4,008,000 | $5,826,000 |
| Current Capital Lease Obligations | $439,000 | $931,000 | $995,000 | $1,042,000 | |||||
| Derivative Liabilities - Short-Term | $0 | ||||||||
| Current Liabilities of Discontinued Operations | View | View | $3,030,000 | $3,162,000 | $816,000 | ||||
| Current Other Liabilities | View | View | $658,000 | $1,438,000 | $759,000 | $1,629,000 | $3,338,000 | $2,012,000 | |
| Current Liabilities | View | View | $56,535,000 | $47,930,000 | $42,064,000 | $35,840,000 | $31,126,000 | $28,613,000 | $28,434,000 |
| Long-Term Debt | View | View | $155,212,000 | $145,930,000 | $157,657,000 | $140,875,000 | $162,840,000 | $193,382,000 | $137,363,000 |
| Capital Lease Obligations - Long-Term | $160,000 | $397,000 | $1,227,000 | $2,337,000 | |||||
| Derivative Liabilities - Long-Term | $2,219,000 | ||||||||
| Commitments and Contingencies | $0 | $0 | $0 | $0 | $0 | $0 | |||
| Deferred Tax Liability | View | View | $22,339,000 | $22,629,000 | $18,240,000 | $18,941,000 | $17,068,000 | $14,875,000 | $10,105,000 |
| Noncurrent Liabilities of Discontinued Operations | View | View | $3,750,000 | $3,762,000 | $2,725,000 | $1,590,000 | |||
| Income Taxes Payable Noncurrent | View | View | |||||||
| Noncurrent Other Liabilities | View | View | $820,000 | $2,848,000 | $5,608,000 | $3,568,000 | |||
| Common Stock - Value (Excluding Additional Paid in Capital) | View | View | $41,196,000 | $39,308,000 | $39,139,000 | $38,116,000 | $38,088,000 | $37,037,000 | $46,700,000 |
| Additional Paid in Capital | View | View | $7,744,000 | $7,342,000 | $7,342,000 | $7,245,000 | $7,245,000 | $7,245,000 | $7,245,000 |
| Amounts Receivable - Officers/Directors for Loans | ($2,097,000) | ($1,652,000) | |||||||
| Retained Earnings | View | View | $79,905,000 | $71,005,000 | $61,369,000 | $54,623,000 | $43,661,000 | $36,279,000 | $28,620,000 |
| Deferred Hedging Gain/(Loss), Net of Tax Effect | $654,000 | $56,000 | |||||||
| Other Unrealized Gain/(Loss) on Marketable Securities, Net of Tax Effect | ($891,000) | ||||||||
| Other Accumulated Comprehensive Income, Net of Tax Effect | View | View | ($1,366,000) | $0 | |||||
| Equity - Other | ($1,648,000) | ($1,382,000) | ($11,538,000) | ($11,538,000) | |||||
| Stockholders' Equity | View | View | $129,499,000 | $117,711,000 | $106,959,000 | $96,970,000 | $87,612,000 | $66,926,000 | $69,375,000 |
| Liabilities and Stockholders' Equity | View | View | $368,155,000 | $337,048,000 | $330,528,000 | $298,573,000 | $302,805,000 | $307,748,000 | $249,204,000 |
| Cash Flow Statement | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
| Operating Activities Beginning Net Income | View | View | $12,189,000 | $11,797,000 | $7,823,000 | $10,962,000 | $7,382,000 | $7,659,000 | $12,024,000 | $10,278,000 |
| Amortization | View | View | $967,000 | $744,000 | $630,000 | $891,000 | ||||
| Depreciation and Amortization | View | View | $30,720,000 | $29,450,000 | $30,549,000 | $27,697,000 | $28,858,000 | $26,402,000 | $22,298,000 | $16,981,000 |
| Adjustment Accretion | View | View | $414,000 | $636,000 | ||||||
| Total Adjustments to Provision for Doubtful Accounts | View | View | $2,091,000 | $3,687,000 | $2,219,000 | $1,530,000 | ||||
| Asset Impairment Charges | View | View | $143,000 | $1,707,000 | $517,000 | $316,000 | $0 | $0 | ||
| Gain/(Loss) on Sale/Retirement of Property, Plant and Equipment | View | View | $1,374,000 | $1,274,000 | ($350,000) | $49,000 | $225,000 | $251,000 | $298,000 | $305,000 |
| Adjustments to Gain/(Loss) on Sale of Business | $720,000 | ($121,000) | $0 | $0 | ||||||
| Adjustment for Equity Based Compensation Expense | View | View | $79,000 | $48,000 | $120,000 | $28,000 | $24,000 | |||
| Adjustment Derivatives | View | View | ($397,000) | $0 | ||||||
| Adjustment Realized Gains Losses On Sale Asset | ($3,482,000) | $359,000 | $1,049,000 | |||||||
| Deferred Income Taxes | View | View | $332,000 | $2,525,000 | ($1,564,000) | $4,304,000 | $1,061,000 | $4,496,000 | $1,451,000 | $2,240,000 |
| Income/(Loss) from Discontinued Operations, Net of Tax Effect | View | View | $184,000 | |||||||
| Adjustment Extraordinary Items | ($1,118,000) | $0 | $0 | |||||||
| Adjustments to Cumulative Effect of a Change in Accounting Principle, Net of Tax Effect | ($1,067,000) | $0 | $0 | |||||||
| Increase/(Decrease) in Receivables | View | View | $7,452,000 | $2,508,000 | $2,188,000 | |||||
| Change Prepaid Expenses Other Current Assets | View | View | ($1,317,000) | ($110,000) | ($306,000) | |||||
| Increase/(Decrease) in Other Non-operating Assets | View | View | ($1,151,000) | $815,000 | $3,964,000 | $1,213,000 | $642,000 | $853,000 | $92,000 | |
| Increase/(Decrease) in Accounts Payable and Accrued Expenses | View | View | $4,530,000 | $4,378,000 | $3,651,000 | |||||
| Increase/(Decrease) in Unearned Premiums | View | View | $1,844,000 | ($519,000) | ($838,000) | |||||
| Change in Liabilities of Discontinued Operations | $1,112,000 | $1,135,000 | $731,000 | ($13,000) | ||||||
| Increase/(Decrease) in Other Non-operating Liabilities | $1,037,000 | |||||||||
| Net Other Increase/(Decrease) in Working Capital | $6,019,000 | ($3,904,000) | $4,146,000 | $6,171,000 | $1,633,000 | |||||
| Net Cash Flows Provided By/(Used In) Operating Activities | View | View | $46,370,000 | $46,484,000 | $39,076,000 | $40,893,000 | $41,187,000 | $35,702,000 | $29,182,000 | $27,456,000 |
| Purchase of Property, Plant and Equipment | View | View | $34,264,000 | $32,199,000 | $29,557,000 | $18,178,000 | $25,012,000 | $42,258,000 | $34,935,000 | $30,005,000 |
| Proceeds from Sales and Principal Collections on Notes Receivable | $0 | |||||||||
| Increase Decrease Restricted Funds | View | View | $175,000 | |||||||
| Acquisition of Businesses, Net of Cash Acquired | View | View | $31,937,000 | $21,785,000 | $39,823,000 | $6,093,000 | $6,995,000 | $43,963,000 | $34,934,000 | $27,649,000 |
| Proceeds from Divestiture of Business | $16,302,000 | $0 | $0 | $0 | ||||||
| Increase Decrease Other Investing Liabilities | $1,644,000 | $48,000 | ||||||||
| Proceeds from Discontinued Operations | View | View | $7,988,000 | $426,000 | ||||||
| Proceeds from Sale of Other Assets | $17,694,000 | $9,897,000 | ||||||||
| Proceeds from Sale of Property, Plant and Equipment | View | View | $3,415,000 | $3,220,000 | $2,510,000 | $1,925,000 | $712,000 | $1,836,000 | $721,000 | $649,000 |
| Net Other Investing Activities | View | View | $7,000 | $1,140,000 | $0 | $247,000 | ||||
| Net Cash Flows Provided By/(Used In) Investing Activities | View | View | ($54,980,000) | ($34,210,000) | ($48,924,000) | ($22,298,000) | ($31,116,000) | ($74,488,000) | ($69,148,000) | ($57,005,000) |
| Reimbursement of loans by employee stock ownership plans | $127,000 | |||||||||
| Loans to employee stock ownership Plans | $266,000 | $286,000 | $446,000 | $147,000 | ||||||
| Proceeds from Related Party Debt | $11,538,000 | $0 | ||||||||
| Other Proceeds from Issuance of Long Term Debt | $57,750,000 | $172,541,000 | ||||||||
| Net Proceeds from Issuance of Long-Term Debt and Capital Securities | View | View | $47,697,000 | $19,010,000 | $40,176,000 | $4,009,000 | $186,809,000 | $114,995,000 | ||
| Reduction of Capital Lease Obligations | View | View | $212,000 | $160,000 | $439,000 | $729,000 | $894,000 | $1,157,000 | $906,000 | $0 |
| Repayments of Long-Term Debt and Capital Securities | View | View | $38,416,000 | $30,727,000 | $24,381,000 | $21,762,000 | $84,802,000 | $118,340,000 | $135,143,000 | $82,527,000 |
| Net Change Notes Payable | ($11,538,000) | |||||||||
| Excess Tax Benefit Stock Option Exercised | View | View | $0 | $0 | ||||||
| Debt Issuance Costs | $1,323,000 | $0 | ||||||||
| Financing Costs | View | View | $68,000 | $39,000 | $2,373,000 | $0 | $0 | |||
| Proceeds from Issuance of Common Stock | $47,000 | $3,250,000 | $0 | |||||||
| Proceeds from Stock Options Exercised | View | View | $2,028,000 | $121,000 | $335,000 | $0 | $1,109,000 | $1,372,000 | $34,000 | $0 |
| Repurchase of Common Stock | $11,006,000 | $0 | $0 | |||||||
| Payment of Dividends | View | View | $3,289,000 | $2,161,000 | $1,077,000 | $0 | $0 | |||
| Distributions to Affiliates | ($790,000) | |||||||||
| Cash Provided by/(Used in) Financing Activities - Other | ($1,327,000) | $1,000 | ||||||||
| Net Cash Flows Provided By/(Used In) Financing Activities | View | View | $7,740,000 | ($13,956,000) | $12,241,000 | ($18,748,000) | ($15,585,000) | $43,011,000 | $39,856,000 | $31,659,000 |
| Increase/(Decrease) in Cash and Cash Equivalents | View | View | ($870,000) | ($1,682,000) | $2,393,000 | ($153,000) | ($5,514,000) | $4,225,000 | ($110,000) | $2,110,000 |
| Cash and cash equivalents at the beginning of the year | View | View | $2,445,000 | $4,127,000 | $1,734,000 | $1,887,000 | $7,401,000 | $3,176,000 | $3,286,000 | $1,176,000 |
| Total Cash and cash equivalents at the end of the year | View | View | $1,575,000 | $2,445,000 | $4,127,000 | $1,734,000 | $1,887,000 | $7,401,000 | $3,176,000 | $3,286,000 |
| Income Taxes Paid | View | View | $3,863,000 | $5,309,000 | $5,513,000 | $3,200,000 | $3,281,000 | $2,954,000 | $4,301,000 | $3,623,000 |
| Cash Interest Expense | View | View | $9,517,000 | $9,203,000 | $9,347,000 | $10,283,000 | $15,342,000 | $12,483,000 | $8,530,000 | $4,926,000 |
| Employee Figures | 2010 |
| Total Employees | View |
| Financial Notes: | |
| * | Par Pharmaceutical Companies, Inc. fiscal year end: 12/31 |
Export All Par Pharmaceutical Companies, Inc. Financials To Excel
$99 Single Company AccessInstant Full Site-Wide AccessPar Pharmaceutical Companies, Inc. Sales Revenue, Net - Goods ($ MM): |
Par Pharmaceutical Companies, Inc. Sales Revenue, Net - Services ($ MM): |
Par Pharmaceutical Companies, Inc. Revenues ($ MM): |
Par Pharmaceutical Companies, Inc. Cost of Goods Sold ($ MM): |
Par Pharmaceutical Companies, Inc. Selling, General and Administrative Expenses ($ MM): |
Par Pharmaceutical Companies, Inc. Depreciation and Amortization ($ MM): |
Par Pharmaceutical Companies, Inc. Asset Impairment Charges ($): |
Par Pharmaceutical Companies, Inc. Expense ($ MM): |
Par Pharmaceutical Companies, Inc. Cost and Operating Expenses ($ MM): |
Par Pharmaceutical Companies, Inc. Operating Income/(Loss) ($ MM): |
Par Pharmaceutical Companies, Inc. Interest Expense ($ MM): |
Par Pharmaceutical Companies, Inc. Interest Income ($ MM): |
Par Pharmaceutical Companies, Inc. Gain/(Loss) on Disposition of Property ($ MM): |
Par Pharmaceutical Companies, Inc. Non-operating Income - Other ($): |
Par Pharmaceutical Companies, Inc. Non-operating Income/(Expense) ($ MM): |
Par Pharmaceutical Companies, Inc. Income/(Loss) from Continuing Operations Before Income Taxes ($ MM): |
Par Pharmaceutical Companies, Inc. Provision for Income Taxes ($ MM): |
Par Pharmaceutical Companies, Inc. Income/(Loss) from Continuing Operations ($ MM): |
Par Pharmaceutical Companies, Inc. Income/(Loss) from Discontinued Operations ($): |
Par Pharmaceutical Companies, Inc. Income/(Loss) from Discontinued Operations, Net of Tax Effect ($ MM): |
Par Pharmaceutical Companies, Inc. Income/(Loss) from Disposition of Discontinued Operations ($ MM): |
Par Pharmaceutical Companies, Inc. Net Income (Loss) ($ MM): |
Par Pharmaceutical Companies, Inc. Cash and Cash Equivalents ($ MM): |
Par Pharmaceutical Companies, Inc. Net Accounts Receivable Trade ($ MM): |
Par Pharmaceutical Companies, Inc. Other Accounts and Notes Receivable ($ MM): |
Par Pharmaceutical Companies, Inc. Net Inventories ($ MM): |
Par Pharmaceutical Companies, Inc. Current Deferred Income Taxes ($ MM): |
Par Pharmaceutical Companies, Inc. Prepaid Insurance ($): |
Par Pharmaceutical Companies, Inc. Current Other Assets ($ MM): |
Par Pharmaceutical Companies, Inc. Current Assets ($ MM): |
Par Pharmaceutical Companies, Inc. Net Property, Plant and Equipment ($ MM): |
Par Pharmaceutical Companies, Inc. Goodwill ($ MM): |
Par Pharmaceutical Companies, Inc. Intangible Assets - Other ($ MM): |
Par Pharmaceutical Companies, Inc. Restricted Cash ($ MM): |
Par Pharmaceutical Companies, Inc. Noncurrent Other Assets ($ MM): |
Par Pharmaceutical Companies, Inc. Assets ($ MM): |
Par Pharmaceutical Companies, Inc. Accounts Payable - Trade ($ MM): |
Par Pharmaceutical Companies, Inc. Self Insurance ($ MM): |
Par Pharmaceutical Companies, Inc. Other Employee Related Liabilities ($ MM): |
Par Pharmaceutical Companies, Inc. Other Accrued Expenses ($ MM): |
Par Pharmaceutical Companies, Inc. Current Deferred/(Unearned) Revenue ($ MM): |
Par Pharmaceutical Companies, Inc. Income Taxes Payable ($ MM): |
Par Pharmaceutical Companies, Inc. Current Portion of Long-Term Debt ($ MM): |
Par Pharmaceutical Companies, Inc. Current Liabilities of Discontinued Operations ($ MM): |
Par Pharmaceutical Companies, Inc. Current Other Liabilities ($ MM): |
Par Pharmaceutical Companies, Inc. Current Liabilities ($ MM): |
Par Pharmaceutical Companies, Inc. Long-Term Debt ($ MM): |
Par Pharmaceutical Companies, Inc. Deferred Tax Liability ($ MM): |
Par Pharmaceutical Companies, Inc. Noncurrent Liabilities of Discontinued Operations ($ MM): |
Par Pharmaceutical Companies, Inc. Income Taxes Payable Noncurrent ($ MM): |
Par Pharmaceutical Companies, Inc. Noncurrent Other Liabilities ($ MM): |
Par Pharmaceutical Companies, Inc. Common Stock - Value (Excluding Additional Paid in Capital) ($ MM): |
Par Pharmaceutical Companies, Inc. Additional Paid in Capital ($ MM): |
Par Pharmaceutical Companies, Inc. Retained Earnings ($ MM): |
Par Pharmaceutical Companies, Inc. Other Accumulated Comprehensive Income, Net of Tax Effect ($ MM): |
Par Pharmaceutical Companies, Inc. Stockholders' Equity ($ MM): |
Par Pharmaceutical Companies, Inc. Liabilities and Stockholders' Equity ($ MM): |
Par Pharmaceutical Companies, Inc. Operating Activities Beginning Net Income ($ MM): |
Par Pharmaceutical Companies, Inc. Amortization ($): |
Par Pharmaceutical Companies, Inc. Depreciation and Amortization ($ MM): |
Par Pharmaceutical Companies, Inc. Adjustment Accretion ($): |
Par Pharmaceutical Companies, Inc. Total Adjustments to Provision for Doubtful Accounts ($ MM): |
Par Pharmaceutical Companies, Inc. Asset Impairment Charges ($ MM): |
Par Pharmaceutical Companies, Inc. Gain/(Loss) on Sale/Retirement of Property, Plant and Equipment ($ MM): |
Par Pharmaceutical Companies, Inc. Adjustment for Equity Based Compensation Expense ($): |
Par Pharmaceutical Companies, Inc. Adjustment Derivatives ($ MM): |
Par Pharmaceutical Companies, Inc. Deferred Income Taxes ($ MM): |
Par Pharmaceutical Companies, Inc. Income/(Loss) from Discontinued Operations, Net of Tax Effect ($ MM): |
Par Pharmaceutical Companies, Inc. Increase/(Decrease) in Receivables ($ MM): |
Par Pharmaceutical Companies, Inc. Change Prepaid Expenses Other Current Assets ($ MM): |
Par Pharmaceutical Companies, Inc. Increase/(Decrease) in Other Non-operating Assets ($ MM): |
Par Pharmaceutical Companies, Inc. Increase/(Decrease) in Accounts Payable and Accrued Expenses ($ MM): |
Par Pharmaceutical Companies, Inc. Increase/(Decrease) in Unearned Premiums ($ MM): |
Par Pharmaceutical Companies, Inc. Net Cash Flows Provided By/(Used In) Operating Activities ($ MM): |
Par Pharmaceutical Companies, Inc. Purchase of Property, Plant and Equipment ($ MM): |
Par Pharmaceutical Companies, Inc. Increase Decrease Restricted Funds ($ MM): |
Par Pharmaceutical Companies, Inc. Acquisition of Businesses, Net of Cash Acquired ($ MM): |
Par Pharmaceutical Companies, Inc. Proceeds from Discontinued Operations ($ MM): |
Par Pharmaceutical Companies, Inc. Proceeds from Sale of Property, Plant and Equipment ($ MM): |
Par Pharmaceutical Companies, Inc. Net Other Investing Activities ($ MM): |
Par Pharmaceutical Companies, Inc. Net Cash Flows Provided By/(Used In) Investing Activities ($ MM): |
Par Pharmaceutical Companies, Inc. Net Proceeds from Issuance of Long-Term Debt and Capital Securities ($ MM): |
Par Pharmaceutical Companies, Inc. Reduction of Capital Lease Obligations ($ MM): |
Par Pharmaceutical Companies, Inc. Repayments of Long-Term Debt and Capital Securities ($ MM): |
Par Pharmaceutical Companies, Inc. Excess Tax Benefit Stock Option Exercised ($): |
Par Pharmaceutical Companies, Inc. Financing Costs ($ MM): |
Par Pharmaceutical Companies, Inc. Proceeds from Stock Options Exercised ($ MM): |
Par Pharmaceutical Companies, Inc. Payment of Dividends ($ MM): |
Par Pharmaceutical Companies, Inc. Net Cash Flows Provided By/(Used In) Financing Activities ($ MM): |
Par Pharmaceutical Companies, Inc. Increase/(Decrease) in Cash and Cash Equivalents ($ MM): |
Par Pharmaceutical Companies, Inc. Cash and cash equivalents at the beginning of the year ($ MM): |
Par Pharmaceutical Companies, Inc. Total Cash and cash equivalents at the end of the year ($ MM): |
Par Pharmaceutical Companies, Inc. Income Taxes Paid ($ MM): |
Par Pharmaceutical Companies, Inc. Cash Interest Expense ($ MM): |
Export Financials to Excel
$99 Single Company AccessInstant Full Site-Wide Access| Date | Status | Target | Buyer | Deal Type | Price | |
| Details | Aug. 2011 | Completed | View | View | Acquisition | View |
| Details | Apr. 2012 | Completed | View1 | View | Acquisition Intellectual Property Sale (IP) | View |
| Details | Jul. 2012 | Completed | View | View | Acquisition Leveraged Buyout (LBO) Take Private | View |
| 1 | Par Pharmaceuticals acquired the rights...Read More → |
Full-length notes are available with Single Report Access or PrivCo Premium Subscription. |
Missing a deal? Tell us about it! tips@privco.com
$99 Single Company AccessInstant Full Site-Wide Access| Date | Deal Type | Action | Resulting Status | Valuation | Amount Raised | Public Ticker | |
| Details | Jul. 2012 | View | View | View | View | View | View |
$99 Single Company AccessInstant Full Site-Wide AccessCOMPANY OVERVIEW
Par Pharmaceutical Companies, Inc., incorporated in 1978 as Par Pharmaceutical, Inc., is a Delaware holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. Par Pharmaceutical Companies, Inc. operates primarily in the United States as two business segments: Par Pharmaceutical (or “Par”), the company’s generic products division, and Strativa Pharmaceuticals (“Strativa”), the company’s branded products division.
Prescription pharmaceutical products are sold as either generic products or branded products. Since the company’s inception, Par Pharmaceutical Companies, Inc. has manufactured, licensed and distributed generic pharmaceutical products.
Par Pharmaceutical Companies, Inc. created a branded products division in 2005. Par Pharmaceutical… Continue Reading →
$99 Single Company AccessInstant Full Site-Wide Access|
Get Full Access To This Report
| or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
PrivCo is the authority for financial & business data on major private companies, including:
| Private Companies | 209,161 |
| Private Investors | 12,020 |
| Private M&A Deals | 43,179 |
| VC/Funding Rounds | 36,104 |
| Total Data Points | 95,786,176 |
You are viewing a free limited preview of Par Pharmaceutical Companies, Inc.
PrivCo is the premier source for business and financial data on major, non-publicly traded corporations, including family owned, private equity owned, venture backed, and international unlisted companies. Click here to learn more.
PDF VERSION: Download Company Report in PDF Format
Full Online Report
